NUVL News and Press, Nuvalent Inc. From 01/08/24

Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones PR Newswire Targeting first approved product in 2026 towards realizing mission of bringing new, potential best-in-class treatments to patients with cancer Well-capitalized to support OnTar...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-24 21:14:00 ET Summary Nuvalent's stock has nearly doubled after positive phase 1 data from its second candidate, NVL-565, targeting ALK-positive NSCLC. The preliminary data showed early anti-tumor activity in heavily pre-treated patients, patients with ALK resistance muta...

Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapie...

2023-12-20 10:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

2023-11-14 06:41:44 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent prices $300 million stock offering Nuvalent announces $300M offering of Class A common stock Seeking Alpha’s Quant Rating on Nuvalent ...

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results PR Newswire Presented preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of ...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Nuvalent Inc. (NUVL) is expected to report $-0.59 for Q3 2023